Investment Rating - The report maintains a "Recommended" rating for the healthcare sector [7] Core Insights - The pharmaceutical sector has shown a slight outperformance against the CSI 300 index, with the Shenwan Pharmaceutical Bio Index rising by 1.16% from April 21 to April 25, 2025, outperforming the CSI 300 by 0.78 percentage points [2][12] - Year-to-date, the Shenwan Pharmaceutical Bio Index has decreased by 0.31%, yet it has outperformed the CSI 300 by 3.45 percentage points, ranking 13th among 31 Shenwan first-level industry indices [2][14] - As of April 25, 2025, the valuation of the pharmaceutical sector stands at 26.37 times (TTM overall method, excluding negative values), with a premium of 141.60% compared to the CSI 300 [2][17] Summary by Sections 1. Market Performance Review - The pharmaceutical sector has shown a mixed performance, with notable individual stock movements, including significant gains for companies like Yong'an Pharmaceutical (+31.37%) and Shutaishen (+28.41%), while companies like *ST Jiyuan experienced substantial declines (-43.24%) [3][18] 2. Important Policies and Events - On April 7, 2025, the Ministry of Commerce and the National Health Commission, among 12 departments, issued the "Special Action Plan to Promote Healthy Consumption," aimed at enhancing the quality of health goods and services to meet the public's needs [4][21] 3. Key Company Announcements - Companies such as Kanghong Pharmaceutical and Yiyue Medical have reported their 2024 annual results, with Kanghong achieving a revenue of 4.453 billion yuan, a year-on-year increase of 12.51%, while Yiyue reported a revenue of 7.566 billion yuan, a decline of 5.09% [22] 4. Industry Perspectives - The report highlights a continued rebound in the pharmaceutical sector, particularly in the innovative drug segment, which is expected to remain a key investment theme for 2025. The focus is shifting from earnings to fundamental changes in the industry and companies as the market enters a performance vacuum period starting in May [5][23][24]

Investment Rating - The industry investment rating is "stronger than the market" [3][47]. Core Viewpoints - The approval of Ivosidenib for first-line treatment of NSCLC in China is a significant milestone, being the first to show positive results in a clinical trial comparing it to Pembrolizumab [3]. - The HARMONi-2 trial demonstrated that Ivosidenib significantly improved progression-free survival (mPFS of 11.14 months vs. 5.82 months for Pembrolizumab), with a hazard ratio (HR) of 0.51, indicating a 49% reduction in the risk of disease progression or death [3]. - The interim analysis of overall survival (OS) at 39% maturity showed a 22.3% reduction in mortality risk for Ivosidenib compared to Pembrolizumab (HR=0.777) [3]. Summary by Sections Industry News - Ivosidenib has received approval for a new indication in first-line treatment of PD-L1 positive locally advanced or metastatic NSCLC based on the HARMONi-2 trial results [3]. - The trial involved a randomized comparison of Ivosidenib and Pembrolizumab, with primary endpoints focused on progression-free survival (PFS) [3]. - Additional studies have shown Ivosidenib's efficacy in various NSCLC settings, including in combination with chemotherapy [4]. Investment Strategy - The report suggests focusing on "innovation," "overseas expansion," "equipment upgrades," and "consumption recovery" as key investment themes [6]. - Companies to watch include innovative drug developers and those with strong overseas market potential, such as BeiGene, Dongcheng Pharmaceutical, and others [6]. Key Companies to Watch - **Nocera Healthcare**: Expected to achieve over 1 billion yuan in revenue from its core product, with a 49% year-on-year growth in sales [7]. - **Sihuan Pharmaceutical**: Strong fundamentals with a stable growth outlook, particularly in the ADC market [10]. - **China Biopharmaceutical**: Rapid revenue growth with a focus on innovative products, particularly in oncology [11]. - **Aier Eye Hospital**: Benefiting from increasing demand for eye care services and a strong pipeline of new products [20].

Investment Rating - The report maintains a "Recommended" rating for the healthcare industry [7] Core Insights - The pharmaceutical sector has shown a slight outperformance against the CSI 300 index, with the Shenwan Pharmaceutical Bio Index rising by 1.16% from April 21 to April 25, 2025, outperforming the CSI 300 by 0.78 percentage points [2] - Year-to-date, the Shenwan Pharmaceutical Bio Index has decreased by 0.31%, yet it has outperformed the CSI 300 by 3.45 percentage points [2][14] - As of April 25, 2025, the valuation of the pharmaceutical sector stands at 26.37 times (TTM overall method, excluding negative values), with a premium of 141.60% compared to the CSI 300 [17] Summary by Sections 1. Market Performance Review - The pharmaceutical sector has outperformed the CSI 300 index during the specified period, ranking 15th among 31 Shenwan first-level industry indices [12] - The top-performing stocks include Yong'an Pharmaceutical (+31.37%), Shutaishen (+28.41%), and Erkang Pharmaceutical (+27.73%) [3][19] 2. Important Policies and Events - On April 7, 2025, the Ministry of Commerce and the National Health Commission, among 12 departments, issued the "Special Action Plan for Promoting Healthy Consumption," aimed at enhancing the quality of health goods and services [4][21] 3. Key Company Announcements - Kanghong Pharmaceutical reported a revenue of 4.453 billion yuan for 2024, a year-on-year increase of 12.51%, with a net profit of 1.191 billion yuan, up 14.02% [22] - Yuyue Medical reported a revenue of 7.566 billion yuan for 2024, a year-on-year decrease of 5.09%, with a net profit of 1.806 billion yuan, down 24.63% [22] 4. Industry Perspectives - The pharmaceutical sector continues to rebound, with the innovative drug segment performing particularly well, alongside upstream research reagent sectors [5][23] - The focus is shifting from earnings to industry and company fundamentals as the market enters a performance vacuum period starting in May [5][23] - The report emphasizes the potential of innovative drugs, overseas markets, and the clearing of centralized procurement as key investment themes for 2025 [5][24]

Policy Developments - The State Council, led by Premier Li Qiang, has discussed and approved the draft of the Medical Security Law, aiming to enhance the medical security policy system and protect the rights of insured individuals [2] - The draft emphasizes the need for stricter supervision of medical insurance funds and the establishment of mechanisms to combat fraudulent medical practices [2] Legislative Updates - The third review of the Infectious Disease Prevention Law revision has been conducted, which includes provisions for timely clarification of false or incomplete infectious disease information by health authorities [3] - The revision also calls for strengthening the disease prevention and control capabilities of medical institutions [3] Regulatory Actions - The National Medical Products Administration (NMPA) has suspended the import of digoxin raw materials from VITAL LABORATORIES PVT. LTD. due to discrepancies in production processes and quality management [4] - The NMPA has mandated that any products made with the affected raw materials must not be released into the market [4] Company Announcements - Weishinkang has received a drug registration certificate for its compound amino acid injection, which is intended for patients with renal insufficiency [6] - Yiling Pharmaceutical's subsidiary has received approval for the listing of letrozole, a drug used in breast cancer treatment [7] Financial Reports - Yixin Tang reported a 79.23% decline in net profit for 2024, with revenues of 18 billion yuan and a net profit of 114 million yuan [9] - Kexing Pharmaceutical's net profit for Q1 2025 increased by 106.21%, with revenues of 354 million yuan [10] - Shengda Bio's Q1 2025 net profit surged by 469.35%, reaching 21.71 million yuan [11] Capital Market Developments - Synaire has completed a multi-million yuan angel round of financing, which will be used for product development and global brand expansion [13] Industry News - The NMPA has identified 10 batches of cosmetics containing banned ingredients, prompting investigations and required corrective actions from involved companies [15] - Tsinghua University has established an AI hospital, aiming to integrate AI with medical services and education [16] - Yuan Da Pharmaceutical's early detection product for urinary tumors has received FDA breakthrough device designation and has commenced clinical application [17] Shareholder Actions - Shareholders of Xiangsheng Medical plan to reduce their holdings by up to 1.72% of the company's shares [19]

每经编辑 张喜威 袁东 国务院总理李强4月27日主持召开国务院常务会议，部署开展美丽河湖保护与建设行动，研究进一步加强困境儿童福利保障有关举措，讨论《中华人民共和 国医疗保障法（草案）》，决定核准浙江三门三期工程等核电项目。（央视新闻） 2 商务部等6部门发通知，事关离境退税 据商务部网站4月27日消息，商务部等6部门发布关于进一步优化离境退税政策扩大入境消费的通知，其中指出，下调离境退税起退点。境外旅客同日同店购 买退税物品金额达到200元人民币，且符合其他相关规定的，可以申请办理离境退税。提升退税商品供给水平。指导退税商店根据境外旅客需求，不断丰富 和优化商品供给，增加老字号产品、中国消费名品、智能产品、非遗产品、工艺美术产品、地理标志产品、文化创意产品、名优特产、体育用品等优质产品 供应。 1 李强主持召开国务院常务会议 商务部：坚定维护多边贸易体制和全球产供链稳定 4月27日，中国与德国就中德汽车产业合作、欧盟对华电动汽车反补贴案等议题进行交流。商务部表示，当前国际形势复杂严峻，个别国家单边主义、保护 主义做法严重破坏国际经贸秩序和全球产供链稳定，汽车行业首当其冲。中国和欧盟是捍卫多边主义和自由贸易的 ...

Group 1 - Haiyuan Composite will implement delisting risk warning from April 29, 2025, with stock name changed to "*ST Haiyuan" and daily price fluctuation limit set at 5% [3] - Xinlaifu plans to acquire 100% of Jin Nan Magnetic Materials, with the transaction expected to constitute a major asset restructuring, and stock will resume trading on April 28, 2025 [4] - Hongbaoli's subsidiary successfully completed trial production of polyether technology transformation project, producing qualified products [5] - Xingguang Co. received a warning letter from Guangdong Securities Regulatory Bureau due to significant discrepancies in 2024 performance forecast and actual results [6] - Meirui New Materials' subsidiary successfully completed the production process for its polyurethane industrial park phase one project [7] Group 2 - Taigang Stainless Steel reported Q1 2025 net profit of 188 million yuan, a year-on-year increase of 5506.92%, with revenue of 23.31 billion yuan, down 4.71% [9] - Shen Shen Fang A reported Q1 2025 net profit of 72.42 million yuan, a year-on-year increase of 3718.51%, with revenue of 330 million yuan, up 457.38% [10] - Qingda Environmental reported Q1 2025 net profit of 68.71 million yuan, a year-on-year increase of 990.26%, with revenue of 619 million yuan, up 317.43% [11] - Jincai Hulin reported Q1 2025 net profit of 13.65 million yuan, a year-on-year increase of 466.95%, with revenue of 206 million yuan, down 33% [13] - New Sai Co. reported Q1 2025 net profit of 18.19 million yuan, a year-on-year increase of 315.74%, with revenue of 1.215 billion yuan, up 312.03% [14] - Kexing Pharmaceutical reported Q1 2025 net profit of 25.58 million yuan, a year-on-year increase of 106.21%, with revenue of 354 million yuan, down 1.97% [15] - Jiechang Drive reported Q1 2025 net profit of 113 million yuan, a year-on-year increase of 62.21%, with revenue of 961 million yuan, up 35.59% [16] - Taihe Co. reported Q1 2025 net profit of 78.53 million yuan, a year-on-year increase of 50.94%, with revenue of 1.033 billion yuan, up 18.5% [17] - Xiyu Co. reported Q1 2025 net profit of 499 million yuan, a year-on-year increase of 53.08%, with revenue of 9.729 billion yuan, up 15.82% [18] - Hualing Cable reported Q1 2025 net profit of 32.16 million yuan, a year-on-year increase of 55.54%, with revenue of 1.005 billion yuan, up 11.38% [19] - Dong'a Ejiao reported Q1 2025 net profit of 425 million yuan, a year-on-year increase of 20.25%, with revenue of 1.719 billion yuan, up 18.24% [20] - China Rare Earth reported Q1 2025 net profit of 72.62 million yuan, turning from loss to profit, with revenue of 728 million yuan, up 141.32% [21] - Gree Electric reported 2024 net profit of 32.185 billion yuan, a year-on-year increase of 10.91%, with revenue of 189.164 billion yuan, down 7.26% [22] - Luzhou Laojiao reported 2024 net profit of 13.473 billion yuan, a year-on-year increase of 1.71%, with revenue of 31.196 billion yuan, up 3.19% [24] - Yake Technology reported 2024 net profit of 872 million yuan, a year-on-year increase of 50.41%, with revenue of 6.862 billion yuan, up 44.84% [25] - Gujing Gongjiu reported 2024 net profit of 5.517 billion yuan, a year-on-year increase of 20.22%, with revenue of 23.578 billion yuan, up 16.41% [26] - Lanzhou Bank reported 2024 net profit of 1.888 billion yuan, a year-on-year increase of 1.29%, with revenue of 7.854 billion yuan, down 2.02% [27] - China Power Construction reported 2024 net profit of 12.015 billion yuan, a year-on-year decrease of 7.21%, with revenue of 633.685 billion yuan, up 4.07% [28] - China Communications Construction reported Q1 2025 net profit of 5.467 billion yuan, a year-on-year decrease of 10.98%, with revenue of 154.644 billion yuan, down 12.58% [29] Group 3 - Koweil plans to reduce its shareholding by up to 3.21% [31] - Nanya New Materials plans to reduce its repurchased shares by up to 238,480 shares, accounting for 1% of total shares [32] - Xiangsheng Medical's shareholders plan to reduce their holdings by up to 1.72% [33] Group 4 - Zhenhua Heavy Industry plans to repurchase shares worth 50 million to 100 million yuan [35] - Deep Keda plans to acquire 16.92% of the equity of its subsidiary Xianma Technology for 47.376 million yuan [37] - Jinchengxin signed a mining production contract with Western Mining, with an estimated contract value of approximately 377 million yuan [38]

以下文章来源于36氪Pro ，作者胡香赟 海若镜 36氪Pro . 文 ｜ 胡香赟 编辑 ｜ 海若镜 来源｜ 36氪Pro（ID：krkrpro） 封面来源 ｜ Pexels 我想"再高一点" 春日，宜万物生长，包括人类幼崽的身高。 在讲究科学的时代，孩子的身高理所应当地也应遵循某种可量化的生长公式。 一个颇受大众认可的方法是，根据父母身高来预测孩子未来的身高区间。比如，男孩子的身高区间=（父亲身高+母亲身高+13厘米）÷2±7.5厘米。 公式前半部分就是所谓的"遗传靶身高"，即由遗传决定的无法改变的身高基数。而后半部分的"±7.5厘米"，则是可以通过后天努力改变的部分——只需 要"充分发挥孩子的生长潜能"。 梁宇在一家药企从事研发工作，出于职业敏感，女儿萱萱还在上幼儿园时，就开始关注她的身高问题。她坦言自己和先生都不算高，对孩子未来的身 高"没有过大期待，她个子不高，这点从小就能看出来"。 尽管如此，萱萱上大班后，梁宇还是开始给她报了跳绳兴趣班。运动、光照、补充维生素D，最初梁宇选择的是最朴素的科学"长个儿"方法。 36氪旗下官方账号。深度、前瞻，为1%的人捕捉商业先机。 如果可以，谁都希望自己的孩子 是人 ...

Group 1 - Since April, the global capital markets have experienced significant volatility, with the A-share market showing recovery after a sharp decline on April 7. Sectors such as leisure food, general retail, beverage and dairy, and agriculture have seen cumulative gains exceeding 11% since April, marking them as bright spots in the market [1] - Multiple brokerage research teams have actively provided professional analysis and macroeconomic outlooks, indicating a strong belief that the upward trend in the Chinese stock market is far from over [1][2] - Central Huijin's liquidity support for stabilizing the stock market has been emphasized, with analysts expressing confidence in the government's commitment to maintaining market stability [2] Group 2 - Analysts predict that the funding environment will remain relatively loose in May, primarily driven by medium to long-term capital entering the market. The focus will shift to technology, green sectors, consumption, and infrastructure in the medium term [3] - The performance of recommended stocks by brokerages has been closely monitored, with 43 brokerages recommending 265 stocks in April, of which 120 stocks outperformed the Shanghai Composite Index, representing 45.28% [5] - Notably, three stocks have seen gains exceeding 50% in April, with Wanchen Group leading at 53.11%, followed by Kexing Pharmaceutical at 52.99%, and Xianda Co. at 51.76% [5][6] Group 3 - The most recommended stock in April was Qingdao Beer, which was recommended by nine brokerages, showing a modest gain of 1.51%. In contrast, Gree Electric, recommended by seven brokerages, experienced a slight decline of 0.53% [6] - The brokerage stock combination index reflects the "mining" capability of brokerage research teams, with only ten brokerage stock combination indices showing an increase since April [6]

证券代码：688136 证券简称：科兴制药 科兴生物制药股份有限公司 2024 年年度股东大会会议资料 科兴生物制药股份有限公司 2024 年年度股东大会 会议资料 $$\Xi{\bf{\mathrm{o}}}\,\Xi{\bf{\mathrm{H}}}\,\Xi{\bf{\mathrm{H}}}\,\Xi$$ 科兴生物制药股份有限公司 2024 年年度股东大会会议资料 科兴生物制药股份有限公司 2024 年年度股东大会会议资料目录 | 2024 | 年年度股东大会会议须知 | 1 | | --- | --- | --- | | 2024 | 年年度股东大会会议议程 | 3 | | 2024 | 年年度股东大会会议议案 | 4 | | | 议案一 关于公司 2024 | 年年度报告及其摘要的议案 4 | | | 议案二 关于公司 2024 | 年度董事会工作报告的议案 5 | | | 议案三 关于公司 2024 | 年度监事会工作报告的议案 6 | | | 议案四 关于公司 2024 | 年度财务决算报告的议案 7 | | | 议案五 关于公司 2024 | 年度利润分配方案的议案 8 | | | 议案六 关 ...

Market Performance - The recombinant protein sector declined by 1.56%, ranking among the top losers in concept sectors as of April 25 [1][2] - Notable stocks within the sector that hit the daily limit down include Jiangsu Wuzhong and Weiming Pharmaceutical, while stocks like HJ Bio, Wanfang Development, and Aladdin saw significant declines [1] Top Gainers and Losers - Among the top gainers in the recombinant protein sector, Borui Pharmaceutical, BeiDa Pharmaceutical, and Tonghua Dongbao increased by 4.39%, 2.42%, and 2.31% respectively [1] - The sector experienced a net outflow of 158 million yuan, with 22 stocks seeing net outflows, and five stocks exceeding 10 million yuan in outflows [2] Capital Flow Analysis - The stock with the highest net outflow was Xilong Science, with a net outflow of 190 million yuan, followed by Furida and Dezhan Health with outflows of 19.41 million yuan and 19.18 million yuan respectively [2][3] - Conversely, the stocks with the highest net inflows included Zhongyuan Qihua, Zhifei Biological, and Chengdu Xian Dao, with inflows of 26.63 million yuan, 25.06 million yuan, and 17.51 million yuan respectively [2][3]